玻璃体内抗血管内皮生长因子药物肾脏不良事件比较:一项Meta分析
该Meta分析纳入11项随机对照试验共10031只眼,比较玻璃体内抗血管内皮生长因子(anti-VEGF)药物与假注射的肾脏不良事件风险。结果显示各anti-VEGF药物与假注射相比急性肾损伤(AKI)风险均无显著差异,但贝伐珠单抗1.25 mg组患者报告症状风险高于阿柏西普2 mg组(RR=3.26,95%CI 1.07-9.93,P=.04),主要由血尿报告驱动。
要点
- 各anti-VEGF药物与假注射相比急性肾损伤风险均无显著差异(所有比较P>.05)。
- 贝伐珠单抗1.25 mg组患者报告症状风险高于阿柏西普2 mg组(RR=3.26,95%CI 1.07-9.93,P=.04)。
- 症状差异主要由血尿报告驱动:贝伐珠单抗4.3%、假注射0.7%、阿柏西普0.2%、法瑞西单抗0.1%、雷珠单抗0.1%。
核心结论
- 美国食品药品监督管理局(FDA)批准的玻璃体内anti-VEGF药物与假注射相比不显著增加急性肾损伤风险。
- 不同anti-VEGF药物间患者报告的肾脏症状存在差异,主要受血尿事件差异影响,可能源于各药物全身吸收不同。
- 上述结果强调持续监测和药物警戒的重要性。
研究设计与样本
- 研究设计为Meta分析,系统检索Ovid Medline、Embase和Cochrane Library中2005年1月至2024年2月发表的随机对照试验(RCT)。
- 纳入接受anti-VEGF玻璃体内注射的成年患者,适应症为年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞继发黄斑水肿。
- 共纳入11项RCT、10031只眼;采用随机效应模型估计风险比(RR)及95%置信区间,P<.05为统计学显著。
- 使用Cochrane ROB2工具评估偏倚风险,采用GRADE框架评价证据确定性。
主要发现
- anti-VEGF药物与假注射在急性或慢性肾脏疾病、梗阻性尿路病变、肿瘤或感染性病变风险方面均无显著差异。
- 急性肾损伤发生率:贝伐珠单抗5.4%(n=10/185)、假注射1.3%(n=6/456)、阿柏西普1.0%(n=48/4724)、法瑞西单抗0.8%(n=15/1929)、布西珠单抗0.5%(n=5/1098)、雷珠单抗0.3%(n=5/1639)。
- 任何anti-VEGF药物与假注射相比急性肾损伤风险均无显著差异(所有比较P>.05)。
- 贝伐珠单抗1.25 mg组患者报告症状风险高于阿柏西普2 mg组(RR=3.26,95%CI 1.07-9.93,P=.04),主要由血尿报告驱动。
- 血尿发生率:贝伐珠单抗4.3%、假注射0.7%、阿柏西普0.2%、法瑞西单抗0.1%、雷珠单抗0.1%。
关键数值与推荐
- 主要结局为anti-VEGF药物与假注射之间急性肾损伤风险的比较。
- 次要结局涉及其他肾脏不良事件。
- 按特定疾病适应症进行亚组分析。
- 采用随机效应模型估计风险比(RR)及95%置信区间,P<.05为统计学显著。
临床怎么用
- 原文结论强调持续监测和药物警戒的重要性。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the risk of renal adverse events, particularly acute kidney injury (AKI), between intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents. DESIGN: Meta-analysis. METHODS: A systematic literature search was conducted on Ovid Medline, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published from January 2005 to February 2024 involving adult patients receiving anti-VEGF intravitreal injections for age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. The primary outcome was the comparative risk of AKI between anti-VEGF agents and sham injections. Secondary outcomes involved other renal adverse events. Subgroup analyses were conducted by specific disease indications. A random-effects model was used for meta-analysis to estimate risk ratios (RRs) and their 95% confidence intervals, with a P value of <.05 representing statistical significance. Risk of bias was assessed using the Cochrane Risk of Bias 2 (ROB2) tool, and the certainty of evidence was evaluated through the Cochrane Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. RESULTS: A total of 10,031 eyes from 11 RCTs were included. No significant differences were found in the risk of acute or chronic renal conditions, obstructive uropathies, neoplasia, or infectious processes between anti-VEGF agents and sham therapy. AKI was reported in 5.4% (n = 10/185) of patients treated with bevacizumab, 1.3% (n = 6/456) with sham, 1.0% (n = 48/4724) with aflibercept, 0.8% (n = 15/1929) with faricimab, 0.5% (n = 5/1098) with brolucizumab, and 0.3% (n = 5/1639) with ranibizumab. No significant differences in AKI risk were observed between any of the anti-VEGF agents and sham (P > .05 for all comparisons). However, there was an increased risk of patient-reported symptoms with 1.25 mg bevacizumab compared to 2 mg aflibercept (RR = 3.26, 95% CI = 1.07-9.93, P = .04), driven primarily by reports of hematuria: 4.3% (bevacizumab), 0.7% (sham), 0.2% (aflibercept), 0.1% (faricimab), and 0.1% (ranibizumab). CONCLUSIONS: US Food and Drug Administration (FDA)-approved intravitreal anti-VEGF agents do not significantly increase the risk of AKI compared to sham injections. Nevertheless, variations in patient-reported renal symptoms were observed across different anti-VEGF drugs. These variations were influenced primarily by differences in hematuria events, which may be a result of differential systemic absorption by these agents. These results underscore the importance of continuous monitoring and pharmacovigilance.
引用
- Huang RS, Balas M, Jhaveri A, et al. Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis. Am J Ophthalmol. 2024. PMID: 39746595. doi:10.1016/j.ajo.2024.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。